APR 27 2026
AstraZeneca — Saphnelo (anifrolumab) $AZN
for systemic lupus erythematosus
FDA approved AstraZeneca's Saphnelo Pen autoinjector for once-weekly subcutaneous self-administration in adult SLE patients.
About
Systemic lupus erythematosus is an autoimmune disease where the immune system mistakenly attacks healthy tissue throughout the body, causing painful flares of joint swelling, fatigue, and rashes. Saphnelo (anifrolumab) is an antibody that blocks a key immune signaling protein called type I interferon. By quieting this overactive immune pathway, the drug may help reduce the frequency and severity of disease flares.
Pivotal trial
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Saphnelo
- AstraZeneca Expands SAPHNELO Into Pediatric Lupus: What Investors Should Watch - TipRanks
- SAPHNELO shows strong sales growth and market p... - Pluang
- Saphnelo (anifrolumab-fnia) for lupus - Lupus News Today
- FDA approves Saphnelo Pen for at-home lupus treatment - Lupus News Today
- FDA approves AstraZeneca’s Saphnelo for SLE - Pharmaceutical Technology